Abstract
Opana® ER (oxymorphone extended release [ER]) is a new oral long-acting formulation indicated for the treatment of moderate to severe chronic pain. Because the ER matrix slowly releases oxymorphone over 12 h, consistent plasma levels are produced with low peak-to-trough fluctuations. Oxymorphone ER is the only long-acting opioid that contains oxymorphone, which exhibits some distinct pharmacologic properties compared with most other opioids, including a longer half-life, higher affinity for the μ-opioid receptor, and lack of interaction with the CYPP450 drug-metabolizing system. With a safety and tolerability profile similar to other opioids and documented efficacy in several models of chronic pain (low back, cancer, and osteoarthritis), oxymorphone ER provides a new option for clinicians and patients in the treatment of chronic pain.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1515-1527 |
| Number of pages | 13 |
| Journal | Expert Opinion on Pharmacotherapy |
| Volume | 8 |
| Issue number | 10 |
| DOIs | |
| State | Published - Jul 2007 |
Fingerprint
Keywords
- Analgesia
- Chronic pain
- Opioids
- Oxymorphone
ASJC Scopus subject areas
- Pharmacology (medical)
- Pharmacology, Toxicology and Pharmaceutics(all)
Cite this
Oral extended-release oxymorphone : A new choice for chronic pain relief. / Matsumoto, Alan K.
In: Expert Opinion on Pharmacotherapy, Vol. 8, No. 10, 07.2007, p. 1515-1527.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Oral extended-release oxymorphone
T2 - A new choice for chronic pain relief
AU - Matsumoto, Alan K.
PY - 2007/7
Y1 - 2007/7
N2 - Opana® ER (oxymorphone extended release [ER]) is a new oral long-acting formulation indicated for the treatment of moderate to severe chronic pain. Because the ER matrix slowly releases oxymorphone over 12 h, consistent plasma levels are produced with low peak-to-trough fluctuations. Oxymorphone ER is the only long-acting opioid that contains oxymorphone, which exhibits some distinct pharmacologic properties compared with most other opioids, including a longer half-life, higher affinity for the μ-opioid receptor, and lack of interaction with the CYPP450 drug-metabolizing system. With a safety and tolerability profile similar to other opioids and documented efficacy in several models of chronic pain (low back, cancer, and osteoarthritis), oxymorphone ER provides a new option for clinicians and patients in the treatment of chronic pain.
AB - Opana® ER (oxymorphone extended release [ER]) is a new oral long-acting formulation indicated for the treatment of moderate to severe chronic pain. Because the ER matrix slowly releases oxymorphone over 12 h, consistent plasma levels are produced with low peak-to-trough fluctuations. Oxymorphone ER is the only long-acting opioid that contains oxymorphone, which exhibits some distinct pharmacologic properties compared with most other opioids, including a longer half-life, higher affinity for the μ-opioid receptor, and lack of interaction with the CYPP450 drug-metabolizing system. With a safety and tolerability profile similar to other opioids and documented efficacy in several models of chronic pain (low back, cancer, and osteoarthritis), oxymorphone ER provides a new option for clinicians and patients in the treatment of chronic pain.
KW - Analgesia
KW - Chronic pain
KW - Opioids
KW - Oxymorphone
UR - http://www.scopus.com/inward/record.url?scp=34447521417&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34447521417&partnerID=8YFLogxK
U2 - 10.1517/14656566.8.10.1515
DO - 10.1517/14656566.8.10.1515
M3 - Article
C2 - 17661733
AN - SCOPUS:34447521417
VL - 8
SP - 1515
EP - 1527
JO - Expert Opinion on Pharmacotherapy
JF - Expert Opinion on Pharmacotherapy
SN - 1465-6566
IS - 10
ER -